British Journal of Cancer · 2011 · 123 citations · 29 references
MedicineOncologyPharmacologyCancer PharmacologyEnzymologyMolecular OncologyAmino Acid MetabolismAutophagy In CancerCancer BiomarkersCancer MetabolismEnzyme InhibitionMetabolic ReprogrammingArginine Deiminase SystemArginine MetabolismArgininosuccinate Synthetase DeficiencyCell Proliferation Inhibition AssaysProliferation AssaysSmall Cell Lung Cancer TherapySmall Cell Lung Cancer TreatmentWestern Blot Analysis
BACKGROUND: Some cancers have been shown to lack expression of argininosuccinate synthetase (ASS), an enzyme required for the synthesis of arginine and a possible biomarker of sensitivity to arginine deprivation. Arginine deiminase (ADI) is a microbial enzyme capable of efficiently depleting peripheral blood arginine. METHODS: Argininosuccinate synthetase expression was assessed in human small cell lung cancer (SCLC) by immunohistochemistry (IHC), with expression also assessed in a panel of 10 human SCLC by qRT-PCR and western blot. Proliferation assays and analyses of apoptosis and autophagy assessed the effect of pegylated ADI (ADI-PEG20) in vitro. The in vivo efficacy of ADI-PEG20 was determined in mice bearing SCLC xenografts. RESULTS: Approximately 45% of SCLC tumours and 50% of cell lines assessed were negative for ASS. Argininosuccinate synthetase-deficient SCLC cells demonstrated sensitivity to ADI-PEG20, which was associated with the induction of autophagy and caspase-independent cell death. Arginine deiminase-PEG20 treatment of ASS-negative SCLC xenografts caused significant, dose-dependent inhibition of tumour growth of both small and established tumours. CONCLUSION: These results suggest a role for ADI-PEG20 in the treatment of SCLC, and a clinical trial exploring this therapeutic approach in patients with ASS-negative SCLC by IHC has now been initiated.
29
Incidence and distribution of argininosuccinate synthetase deficiency in human cancers
Brian J. Dillon, Víctor G. Prieto, Steven A. Curley et al. · Cancer · 2004 · 337 citations
Medicine, Cancer Biology, Oncology +17